Home · Safety · GLP-1 Side Effects

GLP-1 Side Effects: What the FDA Labels Report

Rates from the label trial tables, the serious warnings, and when to get help.

Released: Last reviewed:

Short answer · November 8, 2026

What are the most common side effects of weight-loss GLP-1s? The most common side effects of the FDA-approved weight-loss GLP-1s are gastrointestinal: in the Wegovy 2.4 mg trials 44% of patients had nausea versus 16% on placebo, and in the Zepbound trials 25% to 29% had nausea across the 5 to 15 mg doses versus 8% on placebo. Diarrhea, vomiting and constipation follow. In the labels, 6.8% of Wegovy patients and 4.8% to 6.7% of Zepbound patients stopped treatment because of side effects, against 3.2% and 3.4% on placebo. Most stomach symptoms appear while the dose is being raised.

Most common side effects in the weight-management trials, drug vs placebo (FDA labels read November 8, 2026)
Side effectWegovy 2.4 mgZepbound 5 / 10 / 15 mgFoundayo 5.5 / 9 / 17.2 mg
Nausea44% vs 16%25 / 29 / 28% vs 8%26 / 34 / 35% vs 10%
Diarrhea30% vs 16%19 / 21 / 23% vs 8%21 / 23 / 25% vs 11%
Vomiting24% vs 6%8 / 11 / 13% vs 2%13 / 21 / 24% vs 4%
Constipation24% vs 11%17 / 14 / 11% vs 5%20 / 27 / 24% vs 9%
Abdominal pain20% vs 10%9 / 9 / 10% vs 5%13 / 14 / 14% vs 7%
Stopped for side effects6.8% vs 3.2%4.8 / 6.3 / 6.7% vs 3.4%6 / 9 / 10% vs 3%

Wegovy’s and Zepbound’s tables list reactions seen in at least 2% of treated patients and more often than placebo; Foundayo’s lists those seen in at least 5%. Trial pools differ, so compare rows within a drug more confidently than across drugs. The Wegovy tablets label has no separate symptom table. Full comparison: GLP-1 side effects compared, label data.

Serious warnings in the labels

Every label lists the same core warnings: thyroid C-cell tumors (boxed warning), acute pancreatitis, acute gallbladder disease, hypoglycemia, acute kidney injury from dehydration, severe gastrointestinal reactions, hypersensitivity reactions, diabetic retinopathy complications in people with type 2 diabetes, and pulmonary aspiration during anesthesia or deep sedation. The Wegovy label also lists heart rate increase. The Wegovy and Zepbound labels note that "Suicidal Behavior and Ideation" was removed from their warnings in February 2026.

When to get help

  • Severe stomach pain that does not go away, with or without vomiting (possible pancreatitis).
  • Pain in the upper right abdomen, fever or yellowing skin (gallbladder).
  • Vomiting or diarrhea that stops you keeping fluids down (dehydration and kidney injury).
  • Swelling of the face, lips or throat, or trouble breathing (allergic reaction).
  • A lump or swelling in the neck, trouble swallowing or hoarseness (thyroid).

Compounded versions

Compounded semaglutide and tirzepatide have no FDA label and no trial tables of their own. FDA’s GLP-1 page, current as of October 1, 2026, counts 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide through May 31, 2026, and warns about dosing errors when patients measure doses themselves. See compounding risks and contraindications. Real-world reports are covered in our real-world side effects article.

FAQ

What are the most common side effects of weight-loss GLP-1s?

The most common side effects of the FDA-approved weight-loss GLP-1s are gastrointestinal: in the Wegovy 2.4 mg trials 44% of patients had nausea versus 16% on placebo, and in the Zepbound trials 25% to 29% had nausea across the 5 to 15 mg doses versus 8% on placebo. Diarrhea, vomiting and constipation follow. In the labels, 6.8% of Wegovy patients and 4.8% to 6.7% of Zepbound patients stopped treatment because of side effects, against 3.2% and 3.4% on placebo. Most stomach symptoms appear while the dose is being raised.

Do side effects go away?

The labels report most stomach side effects during dose escalation, which is why doses are raised step by step. If side effects are severe or do not settle, your prescriber may hold or slow the dose increase. Persistent severe abdominal pain needs urgent care.

Which GLP-1 has the most nausea?

In the label tables, nausea was 44% on Wegovy 2.4 mg, 25% to 29% on Zepbound and 26% to 35% on Foundayo, against 8% to 16% on placebo. Because the trial pools differ, these numbers are not a head-to-head comparison; the placebo gap in each trial is a fairer guide.

Do compounded GLP-1s have more side effects?

There is no trial data to say. Compounded products are not FDA-approved and have no label tables. FDA reports adverse-event counts and dosing-error concerns for compounded versions, and notes that reports are likely underreported and do not prove cause.

How many people stop because of side effects?

In the labels, 6.8% of Wegovy 2.4 mg patients versus 3.2% on placebo, 4.8% to 6.7% on Zepbound versus 3.4%, and 6% to 10% on Foundayo versus 3% stopped treatment because of adverse reactions.

Sources

  1. DailyMed — Wegovy (semaglutide) injection and tablets prescribing information, revised 06/2026 (read November 8, 2026)
  2. DailyMed — Zepbound (tirzepatide) prescribing information, revised 08/2026 (read November 8, 2026)
  3. DailyMed — Foundayo (orforglipron) prescribing information, revised 07/2026 (read November 8, 2026)
  4. U.S. FDA — FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of October 1, 2026) (read November 8, 2026)
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 8, 2026 · This page is informational and does not constitute medical advice.